Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)
China · Delayed Price · Currency is CNY 30.67
+5.11 (19.99%)
Sep 30, 2026, 4:00 PM EDT
SHA:688806 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Revenue | 116.93 | 51.22 | 15 | - | 0.33 |
Other Revenue | - | - | 0.06 | - | 4.01 |
| 116.93 | 51.22 | 15.06 | - | 4.34 | |
Revenue Growth | - | 240.23% | - | - | - |
Cost of Revenue | 48.2 | 28.94 | 15.28 | - | 2.78 |
Gross Profit | 68.73 | 22.29 | -0.23 | - | 1.56 |
Selling, General & Admin | 303.17 | 268.41 | 92.45 | 75.24 | 52.26 |
Research & Development | 252.46 | 344.12 | 425.03 | 392.81 | 322.51 |
Other Operating Expenses | 9.51 | 0.65 | 0.08 | 0.02 | -5.81 |
Operating Expenses | 567.42 | 617.51 | 517.59 | 467.79 | 369.1 |
Operating Income | -498.69 | -595.22 | -517.82 | -467.79 | -367.54 |
Interest Expense | -19.91 | -18 | -12.23 | -6.26 | -23.05 |
Interest & Investment Income | 4.55 | 14.02 | 7.6 | 14.12 | 3.54 |
Currency Exchange Gain (Loss) | -2.6 | -1.2 | 0.43 | 0.75 | 4.08 |
Other Non Operating Income (Expenses) | 0.3 | -0.08 | -0.06 | -0.08 | -0.05 |
EBT Excluding Unusual Items | -516.35 | -600.48 | -522.07 | -459.27 | -383.02 |
Gain (Loss) on Sale of Investments | - | - | - | - | -45.62 |
Gain (Loss) on Sale of Assets | -0.01 | 0.22 | 0.61 | 10.8 | 0.13 |
Asset Writedown | -12.79 | -12.79 | -1.58 | -0.46 | -0.17 |
Other Unusual Items | 17.76 | 11.67 | 8.27 | 2.47 | 0.01 |
Pretax Income | -511.39 | -601.38 | -514.77 | -446.45 | -428.67 |
Income Tax Expense | - | - | - | 0 | 0 |
Earnings From Continuing Operations | -511.39 | -601.38 | -514.77 | -446.46 | -428.67 |
Minority Interest in Earnings | 0.84 | 0.06 | - | -0 | 0 |
Net Income | -510.54 | -601.32 | -514.77 | -446.46 | -428.67 |
Net Income to Common | -510.54 | -601.32 | -514.77 | -446.46 | -428.67 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 390 | 385 | 363 | 314 | 160 |
Shares Outstanding (Diluted) | 390 | 385 | 363 | 314 | 160 |
Shares Change | - | 6.33% | 15.30% | 96.56% | - |
EPS (Basic) | -1.31 | -1.56 | -1.42 | -1.42 | -2.68 |
EPS (Diluted) | -1.31 | -1.56 | -1.42 | -1.42 | -2.68 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -509.21 | -602.36 | -385.55 | -329.96 | -362.84 |
Free Cash Flow Per Share | -1.31 | -1.56 | -1.06 | -1.05 | -2.27 |
Gross Margin | 58.78% | 43.51% | -1.50% | - | 35.95% |
Operating Margin | -426.50% | -1161.98% | -3439.31% | - | -8469.02% |
Profit Margin | -436.63% | -1173.88% | -3419.05% | - | -9877.67% |
Free Cash Flow Margin | -435.49% | -1175.92% | -2560.78% | - | -8360.75% |
EBITDA | -472.46 | -569.25 | -493.1 | -445.06 | -349.78 |
D&A For EBITDA | 26.23 | 25.97 | 24.72 | 22.73 | 17.76 |
EBIT | -498.69 | -595.22 | -517.82 | -467.79 | -367.54 |